RonanJKellyMDMBA

Gastrointestinal Cancer, Thoracic Cancer

Director of the Charles A. Sammons Cancer Center and W.W. Caruth Jr. Endowed Chair of Immunology at Baylor University Medical Center Chief of Oncology Baylor Scott & White Health System (NTx) Clinical Professor Texas A&M University Adjunct Associate Professor of Oncology Johns Hopkins Professor Clinical Sciences Division at the Translational Genomics Research Institute (TGEN), Phoenix, Arizona

Join to view full profile

Dr. Kelly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kelly's full profile

Already have an account?

Office
Charles A. Sammons Cancer Center at Baylor University Medical Center
3410 Worth Street, Suite 550
Dallas, TX 75246
Phone+1 214-820-2881

Fax+1 214-820-2846

Summary

Dr. Ronan Kelly is an oncologist in Dallas, TX and is the Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center. He received his medical degree from The Royal College of Surgeons Ireland and has been in practice for over 20 years. He specializes in thoracic malignancies most notably esophageal, gastroesophageal junction, gastric, lung cancers, mesothelioma and thymic malignancies. He remains an adjunct associate professor of oncology at Johns Hopkins and is a clinical professor at Texas A&M University and at the Translational Genomics Research Institute (TGEN) in Phoenix AZ. He is the founder and director of the Texas ImmunoOncology Biorepository (TIOB) and is extensively published in major peer reviewed medical journals.

Education & Training

University College DublinMBA, 2000 - 2001
Royal College of Surgeons IrelandClass of 1998, MB Bch

Certifications & Licensure

MD State Medical License 2011 - 2026
TX State Medical License 2018 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
The Royal College of Physicians in IrelandMember

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

CHFR Methylation Status Esophageal Cancer Study Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) Start of enrollment: 2013 Jul 26
Completed
Phase 1
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Start of enrollment: 2016 Feb 19
Completed
Phase 1
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer Start of enrollment: 2017 Jul 11
Active, not recruiting
Phase 1
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer Start of enrollment: 2019 Mar 06
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and Immun...
Fyza Y Shaikh, Seoho Lee, James R White, Yujie Zhao, Jacqueline T Ferri
Cancers. 2024-10-29
1 citations
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ g...
Harshabad Singh, Kristen E Lowder, Kevin Kapner, Ronan J Kelly, Hui Zheng
Nature Communications. 2024-08-09
2 citations
Immune-related encephalitis after immune checkpoint inhibitor therapy.
Monica W Buckley, Aanika Balaji Warner, Julie Brahmer, Laura C Cappelli, William H Sharfman
The Oncologist. 2024-07-26

Lectures

Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal juncti...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Exact Sciences Announces First Patient Enrolled in Its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence StudyAugust 20th, 2024
New Study Combines AI and Multiomics Analysis to Understand Cancer Resistance MechanismsJanuary 10th, 2023
Breakthrough Research from Baylor Scott & White Health Transforms the Future of Cancer CareJuly 29th, 2021
Join now to see all